Annexin-A1 restricts Th17 cells and attenuates the severity of autoimmune disease. (April 2015)

• Record Type: Journal Article
• Authors: Yazid, Samia; Gardner, Peter J.; Carvalho, Livia; Chu, Colin J.; Flower, Roderick J.; Solito, Egle; Lee, Richard W.J.; Ali, Robin R.; Dick, Andrew D.
• Is Part Of: Journal of autoimmunity. Volume 58(2015)
• Page Start: 1
• Page End: 11
• Publication Date: 2015-04
• Subjects: Annexin-A1 -- Th17 -- Autoimmune -- STAT3 -- SOCS3 -- Uveitis; Anx-A1 Annexin-A1 -- EAU experimental autoimmune uveoretinitis -- RBP retinoid-binding protein; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; Autoantibodies -- Periodicals; Autoimmune Diseases -- Periodicals; Auto-immunité -- Périodiques; Maladies auto-immunes -- Périodiques; Electronic journals; 616.978005
• DOI: 10.1016/j.jaut.2014.12.004
• Languages: English
• ISSNs: 0896-8411

Abstract

Abstract: Annexin-A1 (Anx-A1) is an endogenous anti-inflammatory molecule and while described as a repressor of innate immune responses, the role of Anx-A1 in adaptive immunity, and in particular in T helper (Th) cell responses, remains controversial. We have used a T-cell mediated mouse model of retinal autoimmune disease to unravel the role of Anx-A1 in the development of autoreactive Th cell responses and pathology. RBP1–20 -immunized C57BL/6 Anx-A1 −/− mice exhibit significantly enhanced retinal inflammation and pathology as a result of an uncontrolled proliferation and activation of Th17 cells. This is associated with a limited capacity to induce SOCS3, resulting in un-restricted phosphorylation of STAT3. RBP1–20 -specific CD4 + cells from immunized Anx-A1 −/− animals generated high levels of Th17 cells-associated cytokines. Following disease induction, daily systemic administration of human recombinant Anx-A1 (hrAnx-A1), during the afferent phase of disease, restrained autoreactive CD4 + cell proliferation, reduced expression of pro-inflammatory cytokines IL-17, IFN-γ and IL-6 and attenuated autoimmune retinal inflammatory disease. Furthermore, in man, Anx-A1 serum levels when measured in active uveitis patient sera were low and associated with the detection of IgM and IgG anti-Anx-A1 antibodies when compared to healthy individuals. This data supports Anx-A1 as an early and critical regulator of Th17 cell driven autoimmune diseases such as uveitis. Highlights: Anx-A1 deficiency results in increased autoimmune pathology in mouse. Anx-A1 deficiency results in proliferation and activation of Th17 cells. Autoimmune disease severity can be rescued by administration of hrAnx-A1. Anx-A1 regulates SOCS3/STAT3 signaling to restrain Th17 development. Anx-A1 deficiency is correlated with active uveitis disease in humans.